<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>1560-4381</journal-id>
<journal-title><![CDATA[Correo Científico Médico]]></journal-title>
<abbrev-journal-title><![CDATA[ccm]]></abbrev-journal-title>
<issn>1560-4381</issn>
<publisher>
<publisher-name><![CDATA[Universidad Ciencias Médicas de Holguín]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S1560-43812019000100210</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Papel del antígeno prostático específico en el cribado masivo o individual]]></article-title>
<article-title xml:lang="en"><![CDATA[Prostate-specific antigen role in mass or individual screening]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Sagué Larrea]]></surname>
<given-names><![CDATA[Jorge Luis]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Proaño Lucero]]></surname>
<given-names><![CDATA[Silvia]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Doimeadiós Rodríguez]]></surname>
<given-names><![CDATA[Zulma]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Escuela Superior Politécnica de Chimborazo (ESPOCH) Facultad de Salud Pública ]]></institution>
<addr-line><![CDATA[ ]]></addr-line>
<country>Ecuador</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>03</month>
<year>2019</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>03</month>
<year>2019</year>
</pub-date>
<volume>23</volume>
<numero>1</numero>
<fpage>210</fpage>
<lpage>222</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_arttext&amp;pid=S1560-43812019000100210&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_abstract&amp;pid=S1560-43812019000100210&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://scielo.sld.cu/scielo.php?script=sci_pdf&amp;pid=S1560-43812019000100210&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[RESUMEN El cribado del cáncer prostático con el antígeno prostático específico (PSA) ha sido empleado durante largos años. Sin embargo, en la actualidad muchos estudios aleatorios (randomizados) ponen en duda su utilidad. Se valora la historia del PSA como método de diagnóstico precoz del cáncer de próstata y su papel actual en el cribado, para lo cual se revisaron ensayos clínicos y meta-análisis a nivel mundial. La búsqueda bibliográfica fue realizada principalmente en Medline. Los ensayosEuropean Randomised 55 Study of Screening for Prostate Cancer(ERSPC) y los de Gothenburg han mostrado una ligera disminución de la mortalidad en el grupo de 55 a 69 años de edad, durante 13 años de seguimiento. Los otros ensayos aún nos hacen dudar acerca de los beneficios de la detección precoz, al tener en cuenta: los daños en la calidad de vida, los riesgos del sobrediagnóstico y las complicaciones del tratamiento.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[ABSTRACT Screening for prostate cancer with prostate-specific antigen (PSA) has been used for many years. Nevertheless in present times, many randomized trials call into question its usefulness. In this work, we have evaluated the history of PSA, as a method of diagnosis in prostate cancer and its role in screening at this time. For this, we have made a worldwide review about the main opinions, clinical trials and meta-analysis, related to the current value of the screening for prostate cancer early detection. The bibliographic search was done main in Medline (ERSPC) as well as those of Gothenburg, which have shown a slight decrease in mortality from 55 to 69 age groups, during their 13 years follow-up. Other trials about the benefits of early detection are still in doubt; taking into account quality of life damage, overdiagnosis risks and treatment complications.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[prostático específico]]></kwd>
<kwd lng="es"><![CDATA[PSA]]></kwd>
<kwd lng="es"><![CDATA[cáncer de próstata]]></kwd>
<kwd lng="es"><![CDATA[cribado]]></kwd>
<kwd lng="en"><![CDATA[antigen]]></kwd>
<kwd lng="en"><![CDATA[PSA]]></kwd>
<kwd lng="en"><![CDATA[prostate cancer]]></kwd>
<kwd lng="en"><![CDATA[screening]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zhou]]></surname>
<given-names><![CDATA[CK]]></given-names>
</name>
<name>
<surname><![CDATA[Check]]></surname>
<given-names><![CDATA[DP]]></given-names>
</name>
<name>
<surname><![CDATA[Lortet-Tieulent]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Laversanne]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Jemal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Ferlay]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prostate cancer incidence in 43 populations worldwide: An analysis of time trends overall and by age group]]></article-title>
<source><![CDATA[Int J Cancer]]></source>
<year>2016</year>
<volume>138</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>1388-400</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Stamey]]></surname>
<given-names><![CDATA[TA]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[Hay]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[McNeal]]></surname>
<given-names><![CDATA[JE]]></given-names>
</name>
<name>
<surname><![CDATA[Freiha]]></surname>
<given-names><![CDATA[FS]]></given-names>
</name>
<name>
<surname><![CDATA[Redwine]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prostate-Specific Antigen as a Serum Marker for Adenocarcinoma of the Prostate]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1987</year>
<volume>317</volume>
<numero>15</numero>
<issue>15</issue>
<page-range>909-16</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barry]]></surname>
<given-names><![CDATA[MJ]]></given-names>
</name>
<name>
<surname><![CDATA[Albertsen]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Is Prostate-Specific Antigen Screening "Proven Ineffective Care"?]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2016</year>
<volume>164</volume>
<numero>10</numero>
<issue>10</issue>
<page-range>687-8</page-range></nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Catalona]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
<name>
<surname><![CDATA[Smith]]></surname>
<given-names><![CDATA[DS]]></given-names>
</name>
<name>
<surname><![CDATA[Ratliff]]></surname>
<given-names><![CDATA[TL]]></given-names>
</name>
<name>
<surname><![CDATA[Dodds]]></surname>
<given-names><![CDATA[KM]]></given-names>
</name>
<name>
<surname><![CDATA[Coplen]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
<name>
<surname><![CDATA[Yuan]]></surname>
<given-names><![CDATA[JJJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate Cancer]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>1991</year>
<volume>324</volume>
<numero>17</numero>
<issue>17</issue>
<page-range>1156-61</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Rao]]></surname>
<given-names><![CDATA[AR]]></given-names>
</name>
<name>
<surname><![CDATA[Motiwala]]></surname>
<given-names><![CDATA[HG]]></given-names>
</name>
<name>
<surname><![CDATA[Karim]]></surname>
<given-names><![CDATA[OM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[The discovery of prostate-specific antigen]]></article-title>
<source><![CDATA[BJU Int]]></source>
<year>2008</year>
<volume>101</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>5-10</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Chu]]></surname>
<given-names><![CDATA[TM]]></given-names>
</name>
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[MC]]></given-names>
</name>
<name>
<surname><![CDATA[Papsidero]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<source><![CDATA[Purified human prostate antigen]]></source>
<year>1984</year>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Ruiz López]]></surname>
<given-names><![CDATA[AI]]></given-names>
</name>
<name>
<surname><![CDATA[Pérez Mesa]]></surname>
<given-names><![CDATA[JC]]></given-names>
</name>
<name>
<surname><![CDATA[Cruz Batista]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[González Lorenzo]]></surname>
<given-names><![CDATA[LE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Actualización sobre cáncer de próstata]]></article-title>
<source><![CDATA[CCM]]></source>
<year>2017</year>
<volume>21</volume>
<numero>3</numero>
<issue>3</issue>
</nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Yunda]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Shajaira]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<source><![CDATA[Determinación de PSA total y PSA libre como apoyo al diagnóstico temprano de patologías prostáticas en hombres mayores a 50 años de edad de la parroquia arapicos del Cantón Palora]]></source>
<year></year>
<page-range>140</page-range><publisher-loc><![CDATA[Ecuador ]]></publisher-loc>
<publisher-name><![CDATA[Universidad Técnica de Ambato]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Wang]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
<name>
<surname><![CDATA[Zou]]></surname>
<given-names><![CDATA[Y]]></given-names>
</name>
<name>
<surname><![CDATA[Yang]]></surname>
<given-names><![CDATA[X]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Analysis of the Correlationship between Prostate Specific Antigen Related Variables and Risk Factor in Patients with Prostate Carcinoma]]></article-title>
<source><![CDATA[Cancer Transl Med]]></source>
<year>2015</year>
<volume>1</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>77-9</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Esquivel Parra]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Caicedo Bolaños]]></surname>
<given-names><![CDATA[AM]]></given-names>
</name>
<name>
<surname><![CDATA[Guaitarilla Soto]]></surname>
<given-names><![CDATA[JM]]></given-names>
</name>
<name>
<surname><![CDATA[García Perdomo]]></surname>
<given-names><![CDATA[HA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Una mirada general a los biomarcadores para la tamización y el diagnóstico temprano del cáncer de próstata]]></article-title>
<source><![CDATA[Urol Colombiana]]></source>
<year>2017</year>
<volume>26</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>110-52</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pinsky]]></surname>
<given-names><![CDATA[PF]]></given-names>
</name>
<name>
<surname><![CDATA[Prorok]]></surname>
<given-names><![CDATA[PC]]></given-names>
</name>
<name>
<surname><![CDATA[Kramer]]></surname>
<given-names><![CDATA[BS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prostate Cancer Screening - A Perspective on the Current State of the Evidence]]></article-title>
<source><![CDATA[N Engl J Med]]></source>
<year>2017</year>
<volume>376</volume>
<numero>13</numero>
<issue>13</issue>
<page-range>1285-9</page-range></nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tsodikov]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Gulati]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Heijnsdijk]]></surname>
<given-names><![CDATA[EAM]]></given-names>
</name>
<name>
<surname><![CDATA[Pinsky]]></surname>
<given-names><![CDATA[PF]]></given-names>
</name>
<name>
<surname><![CDATA[Moss]]></surname>
<given-names><![CDATA[SM]]></given-names>
</name>
<name>
<surname><![CDATA[Qiu]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Different Effects of Screening on Prostate Cancer Death in Two Trials]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2017</year>
<volume>167</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>1-16</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Brawley]]></surname>
<given-names><![CDATA[OW]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Prostate Cancer Screening: What We Know, Don't Know, and Believe]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2012</year>
<volume>157</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>135-6</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Jalón Monzón]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Escaf Barmadah]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Viña Alonso]]></surname>
<given-names><![CDATA[LM]]></given-names>
</name>
<name>
<surname><![CDATA[Jalón Monzón]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Aspectos actuales sobre el cribado en el cáncer de próstata]]></article-title>
<source><![CDATA[SEMERGEN]]></source>
<year>2017</year>
<volume>43</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>387-93</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Foley]]></surname>
<given-names><![CDATA[RW]]></given-names>
</name>
<name>
<surname><![CDATA[Maweni]]></surname>
<given-names><![CDATA[RM]]></given-names>
</name>
<name>
<surname><![CDATA[Gorman]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Murphy]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Lundon]]></surname>
<given-names><![CDATA[DJ]]></given-names>
</name>
<name>
<surname><![CDATA[Durkan]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[European Randomised Study of Screening for Prostate Cancer (ERSPC) risk calculators significantly outperform the Prostate Cancer Prevention Trial (PCPT) 2.0 in the prediction of prostate cancer: a multi-institutional study]]></article-title>
<source><![CDATA[BJUI]]></source>
<year>2016</year>
<volume>118</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>706-13</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Hugosson]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Carlsson]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Aus]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bergdahl]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Khatami]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Lodding]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Mortality results from the Göteborg randomised population-based prostate-cancer screening trial]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2010</year>
<volume>11</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>725-32</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carroll]]></surname>
<given-names><![CDATA[PR]]></given-names>
</name>
<name>
<surname><![CDATA[Parsons]]></surname>
<given-names><![CDATA[JK]]></given-names>
</name>
<name>
<surname><![CDATA[Andriole]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Bahnson]]></surname>
<given-names><![CDATA[RR]]></given-names>
</name>
<name>
<surname><![CDATA[Castle]]></surname>
<given-names><![CDATA[EP]]></given-names>
</name>
<name>
<surname><![CDATA[Catalona]]></surname>
<given-names><![CDATA[WJ]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[NCCN Guidelines Insights: Prostate Cancer Early Detection, Version 2.2016]]></article-title>
<source><![CDATA[J Natl Compr Canc Netw]]></source>
<year>2016</year>
<volume>14</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>509-19</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="book">
<collab>Instituto Nacional del Cáncer</collab>
<source><![CDATA[Estudio de Exámenes de Detección de Cáncer de Próstata, Pulmón, Colorrectal y Ovarios (PLCO): preguntas y respuestas]]></source>
<year>2012</year>
<publisher-loc><![CDATA[EE. UU ]]></publisher-loc>
<publisher-name><![CDATA[(NCI)]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Moyer]]></surname>
<given-names><![CDATA[VA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Screening for Prostate Cancer: U.S. Preventive Services Task Force Recommendation Statement]]></article-title>
<source><![CDATA[Ann Intern Med]]></source>
<year>2012</year>
<volume>157</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>120-34</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kilpeläinen]]></surname>
<given-names><![CDATA[TP]]></given-names>
</name>
<name>
<surname><![CDATA[Pogodin-Hannolainen]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Kemppainen]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Talala]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Raitanen]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Taari]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Estimate of Opportunistic Prostate Specific Antigen Testing in the Finnish Randomized Study of Screening for Prostate Cancer]]></article-title>
<source><![CDATA[J Urol]]></source>
<year>2017</year>
<volume>198</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>50-7</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Labajo Robledo]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[PSA y cribado del cáncer de próstata: evidencias científicas]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="book">
<collab>National Cancer Institute</collab>
<source><![CDATA[The Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial: Questions and Answers]]></source>
<year>2012</year>
<publisher-loc><![CDATA[EE. UU ]]></publisher-loc>
<publisher-name><![CDATA[(NCI)]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B23">
<label>23</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Mitropoulos]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Artibani]]></surname>
<given-names><![CDATA[W]]></given-names>
</name>
<name>
<surname><![CDATA[Graefen]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Remzi]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Rouprêt]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Truss]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Notificación y clasificación de complicaciones después de procedimientos quirúrgicos urológicos: una evaluación y recomendaciones del panel de guías clínicas de la EAU]]></article-title>
<source><![CDATA[Act Urol Esp]]></source>
<year>2013</year>
<volume>37</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>1-11</page-range></nlm-citation>
</ref>
<ref id="B24">
<label>24</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Novoa Gómez]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Cruz Walteros]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
<name>
<surname><![CDATA[Rojas Serrano]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Wilde Winz]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Efectos secundarios de los tratamientos del cáncer de próstata localizado en la calidad de vida y el ajuste marital]]></article-title>
<source><![CDATA[Univ Psychol]]></source>
<year>2003</year>
<volume>2</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>169-86</page-range></nlm-citation>
</ref>
<ref id="B25">
<label>25</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Neal]]></surname>
<given-names><![CDATA[DE]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[PSA testing for prostate cancer improves survival-but can we do better?]]></article-title>
<source><![CDATA[Lancet Oncol]]></source>
<year>2010</year>
<volume>11</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>702-3</page-range></nlm-citation>
</ref>
<ref id="B26">
<label>26</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[García González]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Mayayo Dehesa]]></surname>
<given-names><![CDATA[T]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Cancer de próstata: sobretratamiento y sobrediagnóstico]]></article-title>
<source><![CDATA[Arch Españoles Urol]]></source>
<year>2006</year>
<volume>59</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>563-9</page-range></nlm-citation>
</ref>
<ref id="B27">
<label>27</label><nlm-citation citation-type="book">
<collab>Instituto Nacional del Cáncer</collab>
<source><![CDATA[Planificar la transición para la atención del cáncer avanzado en la etapa final de la vida (PDQ(r))-Versión para profesionales de salud]]></source>
<year>2018</year>
<publisher-loc><![CDATA[EE.UU ]]></publisher-loc>
<publisher-name><![CDATA[(NCI)]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B28">
<label>28</label><nlm-citation citation-type="book">
<collab>Instituto Nacional del Cáncer</collab>
<source><![CDATA[Cuidados médicos cuando el tratamiento puede no ser una opción]]></source>
<year>2018</year>
<publisher-loc><![CDATA[EE.UU ]]></publisher-loc>
<publisher-name><![CDATA[(NCI)]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B29">
<label>29</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Djulbegovic]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Beyth]]></surname>
<given-names><![CDATA[RJ]]></given-names>
</name>
<name>
<surname><![CDATA[Neuberger]]></surname>
<given-names><![CDATA[MM]]></given-names>
</name>
<name>
<surname><![CDATA[Stoffs]]></surname>
<given-names><![CDATA[TL]]></given-names>
</name>
<name>
<surname><![CDATA[Vieweg]]></surname>
<given-names><![CDATA[J]]></given-names>
</name>
<name>
<surname><![CDATA[Djulbegovic]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Screening for prostate cancer: systematic review and meta-analysis of randomised controlled trials]]></article-title>
<source><![CDATA[BMJ]]></source>
<year>2010</year>
<volume>341</volume>
<page-range>4543</page-range></nlm-citation>
</ref>
<ref id="B30">
<label>30</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sagué Larrea]]></surname>
<given-names><![CDATA[JL]]></given-names>
</name>
</person-group>
<source><![CDATA[Urología]]></source>
<year>2012</year>
<publisher-loc><![CDATA[La Habana ]]></publisher-loc>
<publisher-name><![CDATA[Ciencias Médicas]]></publisher-name>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
